Strainprint Featured in The Growth Op – Strainprint announces research partnership to identify how cannabis can be used to treat endometriosis
Strainprint announces research partnership to identify how cannabis can be used to treat endometriosis
Strainprint™ Technologies, Lumir Lab and Gynica Announce Clinical Trial Partnership Establishing World’s First and Largest Database of Medical Cannabis Effects on Women
International Study Monitoring Real-time Cannabis Treatment for the Symptoms of Endometriosis Will Leverage Strainprint’s Comprehensive Research Platform
Strainprint Featured in the Growth Op – Online, cannabis education resource offers patients, canna-curious consumers a safe space
Online, cannabis education resource offers patients, canna-curious consumers a safe space
Strainprint Featured in the Green Market Report – Cannabis Company President Applies Tech Boom Lessons to Cannabis Industry
Cannabis Company President Applies Tech Boom Lessons to Cannabis Industry
Strainprint Featured in CTV News – Canadian tech companies look to cash in on cannabis with innovations and apps
Strainprint, which has focused on medical marijuana users but works just as well for recreational users, launched the day before legalization to take advantage of the attention pot would garner.
Strainprint Featured in Toronto.com – Canadian Medical Marijuana Analytic App Expands As Pot Becomes Legal
Strainprint Community allows cannabis users to share information
Strainprint Featured in MNP- Meet the Industry: Conversations with Canada’s Cannabis Leaders
MNP has partnered with Business of Cannabis to share the stories of people, businesses and brands who are building Canada’s cannabis sector from the ground up.
Strainprint™ Technologies Ltd. expands nationwide coverage with the addition of GrowWise Health Education Centres
Enterprise-wide license to Strainprint Analytics, Clinic Edition, will provide unparalleled medical cannabis treatment guidance.
Strainprint Featured in the Regina Leader-Post
For those aged 50 and older, men edged out women with respect to reporting efficacy of top-treated symptoms.